Jag Capital Management, LLC Gilead Sciences, Inc. Transaction History

Jag Capital Management, LLC

$821 Million
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$73.27 - $83.09 $6,594 - $7,478	90 Added 0.56%	16,235 $1.32 Million
Q3 2023 Nov 15, 2023	BUY	$73.94 - $80.67 $45,694 - $49,854	618 Added 3.98%	16,145 $1.21 Million
Q2 2023 Sep 07, 2023	BUY	$76.01 - $86.7 $19,230 - $21,935	253 Added 1.66%	15,527 $1.2 Million
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $76,998 - $87,827	1,013 Added 6.98%	15,527 $1.2 Million
Q1 2023 Sep 07, 2023	SELL	$77.31 - $88.08 $102,976 - $117,322	-1,332 Reduced 8.02%	15,274 $1.27 Million
Q1 2023 Sep 01, 2023	SELL	$77.31 - $88.08 $102,976 - $117,322	-1,332 Reduced 8.02%	15,274 $1.27 Million
Q1 2023 May 10, 2023	BUY	$77.31 - $88.08 $4,561 - $5,196	59 Added 0.41%	14,514 $1.2 Million
Q4 2022 Sep 07, 2023	BUY	$62.32 - $89.47 $67,243 - $96,538	1,079 Added 6.95%	16,606 $1.43 Million
Q4 2022 Sep 01, 2023	BUY	$62.32 - $89.47 $67,243 - $96,538	1,079 Added 6.95%	16,606 $1.43 Million
Q4 2022 Feb 08, 2023	BUY	$62.32 - $89.47 $4,549 - $6,531	73 Added 0.51%	14,455 $1.24 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $1,845 - $2,108	-31 Reduced 0.22%	14,382 $887,000
Q2 2022 Aug 01, 2022	SELL	$57.72 - $65.01 $253,968 - $286,044	-4,400 Reduced 23.39%	14,413 $891,000
Q1 2022 May 11, 2022	BUY	$57.92 - $72.58 $165,361 - $207,215	2,855 Added 17.89%	18,813 $1.22 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $1,881 - $2,135	-29 Reduced 0.18%	15,958 $1.16 Million
Q3 2021 Oct 21, 2021	SELL	$67.69 - $73.03 $229,604 - $247,717	-3,392 Reduced 17.5%	15,987 $1.12 Million
Q2 2021 Jul 23, 2021	BUY	$63.47 - $69.35 $2,919 - $3,190	46 Added 0.24%	19,379 $1.33 Million
Q1 2021 Apr 23, 2021	SELL	$60.0 - $68.46 $31,380 - $35,804	-523 Reduced 2.63%	19,333 $1.25 Million
Q4 2020 Feb 01, 2021	SELL	$56.65 - $64.55 $57,896 - $65,970	-1,022 Reduced 4.9%	19,856 $1.16 Million
Q3 2020 Oct 21, 2020	BUY	$62.1 - $78.08 $36,763 - $46,223	592 Added 2.92%	20,878 $1.32 Million
Q2 2020 Jul 23, 2020	SELL	$72.34 - $84.0 $11.2 Million - $13 Million	-154,468 Reduced 88.39%	20,286 $1.56 Million
Q1 2020 Apr 16, 2020	BUY	$62.63 - $80.22 $10 Million - $12.9 Million	160,303 Added 1109.29%	174,754 $13.1 Million
Q4 2019 Jan 27, 2020	BUY	$61.62 - $67.78 $2,279 - $2,507	37 Added 0.26%	14,451 $939,000
Q3 2019 Oct 24, 2019	SELL	$62.51 - $69.0 $91,452 - $100,947	-1,463 Reduced 9.21%	14,414 $914,000
Q2 2019 Jul 22, 2019	BUY	$61.87 - $69.38 $13,487 - $15,124	218 Added 1.39%	15,877 $1.07 Million
Q1 2019 Apr 15, 2019	BUY	$62.53 - $70.05 $5,940 - $6,654	95 Added 0.61%	15,659 $1.02 Million
Q4 2018 Jan 16, 2019	SELL	$60.54 - $79.0 $57,210 - $74,655	-945 Reduced 5.72%	15,564 $974,000
Q3 2018 Oct 23, 2018	BUY	$71.28 - $78.92 $1,995 - $2,209	28 Added 0.17%	16,509 $1.28 Million
Q2 2018 Jul 20, 2018	BUY	$64.88 - $75.68 $4,087 - $4,767	63 Added 0.38%	16,481 $1.17 Million
Q4 2017 Jan 23, 2018	SELL	$71.15 - $83.52 $75,774 - $88,948	-1,065 Reduced 6.09%	16,418 $1.18 Million
Q3 2017 Oct 16, 2017	BUY	$72.11 - $85.47 $1.26 Million - $1.49 Million	17,483	17,483 $1.42 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jag Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jag Capital Management, LLC with notifications on news.

Account